World antibacterials market to grow to $43.8 billion in 2016, says Visiongain

World revenues for antibacterial drugs will reach $43.81 billion in 2016. Between 2010 and 2022, the global market will expand with a compound annual growth rate (CAGR) of 2.2%, according to the findings of a new report from business information firm Visiongain, titled Antibacterial Drugs: World Market Prospects 2012-2022.

Visiongain predicts that cephalosporins will remain the largest sector of the market throughout the forecast period, with revenues growing to $11.67 billion by 2016. The fastest growing class of antibacterial drug will be the carbapenems, revenues for which will grow with a CAGR of 3% between 2010 and 2022. Increased uptake in place of other drug classes will drive this growth, as will the class's low susceptibility to bacterial resistance.

A Visiongain pharmaceutical industry analyst, said: "The market will rely on strong uptake of new drugs, such as Ortho-McNeil/Shionogi's Doribax (doripenem for injection), to drive growth to 2022. However, newer drugs will find it increasingly difficult to reach blockbuster status, given the high level of generic competition expected in the market this decade."